According to Kotak Institutional Equities, the market is severely undervaluing ITC Ltd. (NSE: ITC) by pricing its core tobacco division at an implied one-year forward price-to-earnings multiple of roughly 11X. Analysts argue this pessimistic valuation assumes perpetual stagnation or ignores the strong cash generation capacity of the enterprise.
The Bottom Line
- The Core Disconnect: Kotak’s reverse-SoTP analysis implies the tobacco segment trades at an 11X forward multiple, failing to match global sector baselines.
- The Valuation Breakdown: The brokerage assigns a 16X multiple to September 2028E tobacco earnings (fair value of Rs 194) and a 30X multiple to non-tobacco EBITDA (fair value of Rs 80).
- The Catalyst: A potential vertical split of the corporate entity could isolate ESG-wary institutional capital from steady dividend-yielding tobacco assets.
Decoding the 11X Forward P/E Discount
Market pricing often reveals behavioral extremes. In the case of ITC Ltd. (NSE: ITC), the current valuation metric suggests investors expect tobacco earnings to flatline indefinitely. Here is the math: Kotak Securities pegs the implied one-year forward P/E of the tobacco division around 11X based on depressed FY2027-28E estimates compared to FY2026 levels.
But the balance sheet tells a different story. Kotak’s baseline relies on a 16X multiple applied to September 2028E earnings for the tobacco business. This framework generates a 12-month fair value of Rs 194 for the segment alone. The implied growth rate sits between 4.8% and 5.8% in perpetual free cash flow to equity (FCFE), aligning closely with the long-term projections of major international tobacco operators.
If the market refuses to pay up, it signals either profound skepticism toward near-term earnings forecasts or a broad reluctance to hold sin stocks due to modern portfolio mandates.
Weighing the Non-Tobacco Growth Engine
Beyond cigarettes and paperboards, ITC operates a massive FMCG, hotels, and agribusiness portfolio. Kotak pushes back against this narrative by assigning a 30X two-year forward EV/EBITDA multiple to the non-tobacco business.
Admittedly, a 30X multiple looks aggressive against a backdrop of recent multiple deratings across consumer goods peers. Yet, execution velocity matters. ITC is expanding market share in underpenetrated categories while unlocking operating leverage as facilities scale. This dynamic justifies a premium valuation for the non-tobacco arm.
| Segment | Valuation Methodology | Multiple | 12-Month Fair Value Per Share |
|---|---|---|---|
| Tobacco Business | September 2028E Earnings | 16X P/E | Rs 194 |
| Non-Tobacco Business | September 2028E EBITDA | 30X EV/EBITDA | Rs 80 |
| Other Businesses & Cash | Sum-of-the-Parts Allocation | N/A | Rs 84 |
The non-tobacco valuation accounts for an isolated contribution of Rs 80 per share, while cash and remaining ancillary operations add another Rs 84. When aggregated, these figures point toward a significant valuation mismatch.
Unlocking Shareholder Value Through Corporate Restructuring
Conglomerate discounts rarely evaporate on their own. They require structural surgery. Kotak suggests that a vertical split dividing ITC into two distinct corporate entities could fundamentally alter the investor base.
Housing the tobacco cash machine in a dedicated entity would immediately attract value-oriented investors hunting for high dividend yields and durable cash flows. Meanwhile, the standalone non-tobacco enterprise would court growth-focused funds previously restricted by ESG exclusionary screens. By removing the ESG friction, institutional participation could expand meaningfully.
As financial markets continue to re-evaluate industrial conglomerates in high-inflation environments, capital allocation clarity remains the ultimate currency. Whether management pursues a formal corporate split or lets the sum-of-the-parts argument play out organically, the current equity pricing leaves an inviting margin of safety for patient capital.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
Related reading
